AstraZeneca PLC (AZN)

NYQ – Real Time Price. Currency in USD

184.54

+2.68 (1.47%)

At close: May 12, 2026, 4:00 PM EDT

186.05

+1.51 (0.82%)

Pre-market: May 13, 2026, 4:18 AM EDT

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

04.05.2026

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.

02.05.2026

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

01.05.2026

AstraZeneca stock falls after FDA panel votes against new cancer drug

An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. AstraZeneca's London-listed shares fell on the back of the vote outcome.

01.05.2026

AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back its camizestrant treatment in a key breast cancer setting. The FTSE 100 drugmaker said the Oncologic Drugs Advisory Committee of the Food and Drug Administration (FDA) voted three to six against the benefit-risk profile of camizestrant in combination with a CDK4/6 inhibitor for first-line treatment of advanced hormone receptor-positive breast cancer.

01.05.2026

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.

01.05.2026

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Shares of AstraZeneca fell ‌1.7% on Friday after an advisory ⁠panel for the U.S. Food and Drug Administration overnight voted ‌against ⁠recommending the British drugmaker's experimental breast ⁠cancer treatment.

Videos

19.12.2025

Neutral

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

01.12.2025

Neutral

BREAKING: Trump strikes major deal with UK on drug pricing

22.11.2025

Positive

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

14.11.2025

Positive

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Press releases

29.04.2026

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.

27.04.2026

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III TULIP-SC trial, which showed that subcutaneous (SC) administration of SAPHNELO led to a statistically significant and.

20.04.2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. I.

27.03.2026

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Toz.

AstraZeneca PLC (AZN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AstraZeneca PLC (AZN)

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Videos

Press releases

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Videos

Press releases

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

Search stocks

AstraZeneca PLC (AZN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AstraZeneca PLC (AZN)

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Videos

Press releases

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AstraZeneca stock falls after FDA panel votes against new cancer drug

AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Videos

Press releases

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD